What laboratory tests should be obtained and monitored for a patient on antipsychotic medication?

Laboratory Monitoring for Patients on Antipsychotics

All patients starting antipsychotic treatment require baseline metabolic and cardiac screening, followed by structured monitoring at 4 weeks, 3 months, and annually thereafter, with clozapine requiring additional weekly-to-monthly blood count monitoring for the first 2 years. 1

Baseline Testing (Before Starting Any Antipsychotic)

Obtain the following parameters before initiating antipsychotic treatment 1:

• Metabolic parameters:

  • BMI and waist circumference
  • Fasting glucose or HbA1c (if fasting sample unavailable, random glucose is acceptable for initial screening, but follow up with fasting if abnormal)
  • Lipid panel (total cholesterol, LDL, HDL, triglycerides)

• Hematologic and biochemical:

  • Complete blood count (CBC)
  • Liver function tests
  • Urea and electrolytes (renal function)
  • Prolactin level

• Cardiovascular:

  • Blood pressure
  • Electrocardiogram (ECG)

Follow-Up Monitoring Schedule

First 6 Weeks

• Weekly monitoring of BMI, waist circumference, and blood pressure for the first 6 weeks 1
• At 4 weeks: Repeat fasting glucose 1

At 3 Months

Repeat all baseline parameters 1:

• BMI, waist circumference, blood pressure
• HbA1c and lipids
• Prolactin, liver function, renal function, CBC

Annual Monitoring (After First Year)

Repeat all baseline parameters annually 1

Special Considerations for Clozapine

Clozapine requires the most intensive monitoring due to risk of agranulocytosis and multiple adverse drug reactions. 2

Hematologic Monitoring for Clozapine

• Weekly absolute neutrophil count (ANC) for first 18 weeks
• Every 4 weeks from week 18 until 2 years post-commencement
• Annual complete blood count after 2 years (for hematological malignancy screening) 2
• ANC threshold for concern: <1.0×10⁹ cells/L (or <0.5×10⁹ cells/L for benign ethnic neutropenia/DARC-null individuals) 2

Adverse Drug Reaction Monitoring for Clozapine

Monitor at each ANC appointment for first 2 years, then every 3 months 2:

• Metabolic syndrome parameters
• Constipation and gastrointestinal hypomotility (critical—can be life-threatening)
• Gastroesophageal reflux, sialorrhea, sedation
• Orthostatic hypotension, tachycardia
• Nocturnal enuresis, seizures, myoclonus
• Sleep apnea, pneumonia risk
• Sexual dysfunction, heart failure symptoms

Additional Clozapine-Specific Tests

• Clozapine plasma levels: Annually and with any change in smoking, infection/inflammation, mental state changes, new sedation/myoclonus, or when CYP1A2 inhibitors are added/stopped 2
• ECG: Consider annually (though not reaching full consensus in guidelines) 2
• Echocardiogram: Only if clinically indicated, not routinely 2

Medication-Specific Monitoring Adjustments

High Metabolic Risk Agents (Olanzapine, Clozapine)

• Consider more frequent metabolic monitoring (quarterly rather than annually) 3
• If prescribing adjunctive metformin for metabolic protection, add annual vitamin B12 monitoring 1

Prolactin-Elevating Agents (Risperidone, Paliperidone, Amisulpride, First-Generation Antipsychotics)

• Monitor prolactin levels at baseline and if symptoms develop (menstrual irregularities, galactorrhea, sexual dysfunction)
• Counsel patients on risks of chronic hyperprolactinemia including reduced bone density and increased breast cancer risk in women 1

Common Pitfalls to Avoid

1. Laboratory monitoring is frequently inadequate in real-world practice—physical parameters like weight are monitored more consistently (86% in first 6 months) than laboratory parameters like glucose and lipids (only 24%) 4

2. Don't skip baseline testing—studies show baseline testing rates as low as 0-45% for various parameters 5, yet this is essential for detecting treatment-emergent changes

3. Document reasons when monitoring cannot be performed—patient/family refusal or monitoring by primary care should be explicitly noted 4

4. For clozapine, after 2 years of stable treatment, strongly consider alternative causes before discontinuing for low ANC—the threshold for concern remains important but clinical judgment should weigh other factors 2

5. Fasting samples are ideal but pragmatism matters—if fasting glucose cannot be obtained, use random glucose for screening and follow up with fasting if abnormal 1